Trial Profile

Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary) ; Furosemide
Indications Decompensated heart failure
Focus Pharmacodynamics
Acronyms EMPAG-HF

Most Recent Events

29 Jun 2022 Primary endpoint has been met. (Total urinary output (UOP) as measured by daily volume summed up over 5 days), as per Results published in the Circulation
29 Jun 2022 Results published in the Circulation
22 Jul 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com